Completed PHASE1 INTERVENTIONAL 1-arm NCT00970346

Safety and Efficacy of Inhaled OligoG CF-5/20 for the Treatment Cystic Fibrosis

A Randomised, Double-blind, Placebo-controlled Dose-escalation Phase I Study to Evaluate the Safety and Tolerability of Inhaled Aerosolised OligoG CF-5/20 (G-block Oligosaccharide Derived From Alginate Polysaccharide) in Healthy Volunteers

Sponsor: AlgiPharma AS

Conditions Cystic Fibrosis

Interventions OligoG CF-5/20

Updated 5 times since 2017 Last updated: Mar 22, 2016 Started: Sep 30, 2009 Primary completion: Oct 31, 2009 Completion: Nov 30, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00970346, this PHASE1 trial focuses on Cystic Fibrosis and remains completed. Sponsored by AlgiPharma AS, it has been updated 5 times since 2009, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Sep 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AlgiPharma AS
Smerud Medical Research International AS

Data source: AlgiPharma AS

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Merthyr Tydfil, United Kingdom